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Abstract
Glioblastoma multiforme is the most common and malignant primary brain tumor. Recent evidence indicates that a subset
of glioblastoma tumor cells have a stem cell like phenotype that underlies chemotherapy resistance and tumor recurrence.
We utilized a new ‘‘multidimensional’’ capillary isoelectric focusing nano-reversed-phase liquid chromatography platform
with tandem mass spectrometry to compare the proteomes of isolated glioblastoma tumor stem cell and differentiated
tumor cell populations. This proteomic analysis yielded new candidate proteins that were differentially expressed.
Specifically, two isoforms of the membrane proteolipid neuronatin (NNAT) were expressed exclusively within the tumor
stem cells. We surveyed the expression of NNAT across 10 WHO grade II and III gliomas and 23 glioblastoma (grade IV)
human tumor samples and found NNAT was expressed in a subset of primary glioblastoma tumors. Through additional in
vitro studies utilizing the U87 glioma cell line, we found that expression of NNAT is associated with significant increases in
cellular proliferation. Paralleling the in vitro results, when NNAT levels were evaluated in tumor specimens from a
consecutive cohort of 59 glioblastoma patients, the presence of increased levels of NNAT were found to be a an
independent risk factor (P = 0.006) for decreased patient survival through Kaplan-Meier and multivariate analysis. These
findings indicate that NNAT may have utility as a prognostic biomarker, as well as a cell-surface target for chemotherapeutic
agents.
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Introduction
Glioblastoma Multiforme (GBM) is the most common and
deadly (median survival of 1 year) adult central nervous system
malignancy. Recent evidence demonstrates that a subset of GBM
tumor cells harbor an undifferentiated stem cell-like phenotype
and are refractory to conventional chemotherapeutic agents [1,2].
To elucidate phenotypic markers of these tumor stem cells (TSCs),
we previously utilized 2-dimensional polyacrylamide gel electro-
phoresis (2D-PAGE) for comparative proteomic analysis of GBM
and normal brain tissue [3]. However, 2D-PAGE is significantly
limited by its qualitative nature for detection of proteins in low
cellular concentrations and the sample preparation requirements
are incompatible with hydrophobic proteins including membrane
bound proteins. These limitations preclude the identification of
many candidate TSC markers, including membrane bound
proteins that are potential chemotherapeutic targets.
To overcome the technical limitations of 2D-PAGE described
above and to gain deeper insight into the potential TSC protein
markers, we utilized a new method of ‘‘multidimensional’’
capillary isoelectric focusing nano-reversed-phase liquid chroma-
tography with tandem mass spectroscopy (CIEF-nRPLC-MS) to
compare the proteomes of primary TSC cultures before and after
induction of differentiation with ciliary neurotrophic factor
(CNTF) [4]. CIEF-nRPLC-MS permits a 15-fold increase in
protein identification compared to 2D-PAGE and is fully
compatible with preparations isolating hydrophobic proteins.
Subsequently, application of CIEF-nRPLC-MS permits the highly
sensitive and reliable identification and quantitative comparison of
proteins between different isolated cell populations.
Using CIEF-nRPLC-MS, we isolated a number of TSC
membrane proteins that showed at least a 3 log-fold difference
in expression after differentiation. Among these, both a and b
isoforms of the proteolipid, neuronatin (NNAT), were found to be
consistently expressed in TSCs but non-existent within their
differentiated counterparts. Given the putative involvement of
NNAT with the embryological development of the CNS, as well as
reports of its association with more aggressive phenotypes in
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medulloblastoma [5–7], we sought to confirm the proteomic
finding of upregulated NNAT in GBM TSCs and to establish its
utility as a prognostic biomarker in GBM patients. We then
addressed its putative biological role and potential signaling
mechanisms through in vitro transfection of the human glioma cell
line U87 with fluorescent protein tagged constructs.
Our findings indicate that NNAT is endogenously expressed at
low levels in normal human brain tissue, but becomes over
expressed in a subset of primary GBM tumors. When transfected
into U87 glioma cells, both isoforms of NNAT were associated
with significant increases in cellular proliferation. Furthermore,
high levels of NNAT expression were correlated to significantly
shorter overall survival in a separate cohort of GBM patients. The
molecular mechanisms underlying this effect have yet to be
elucidated, but given NNAT’s expression pattern, it may play a
specific role in the pathogenesis or maintenance of primary GBM
TSCs.
Results
CIEF-nRPLC-MS identifies differential NNATa and NNATb
expression in undifferentiated and differentiated TSCs
TSCs were established from human GBM tissue. Cultured cells
were maintained in an undifferentiated state, confirmed by
positive immunocytochemical staining for the neural stem cell
markers Nestin and Sox2. Differentiation of TSCs was induced by
treatment with CNTF and demonstrated by loss of Nestin and
Sox2 expression, as well as concomitant gain of GFAP expression
as previously described [3].
Both undifferentiated and CNTF-treated differentiated glioma
TSCs were analyzed using CIEF-nRPLC-MS/MS. Peptide
identification was based on 3 runs of a single tissue sample and
was limited by high-mass-accuracy (60 ppm) and high-confidence
(5% false-positive) hits to fully tryptic proteins. Expression
differences between the undifferentiated and the differentiated
TSC proteomes yielded 174 membrane proteins. Among those
proteins, both NNATa and NNATb were identified to have
greater than 3-log fold levels in TSCs prior to differentiation with
near undetectable levels found in the differentiated cells.
NNAT is expressed in a subset of normal glial cells
To assess the efficiency and specificity of a commercial antibody
derived against NNAT, we used western blotting to probe for
NNAT in brain tumor derived cell lines (U87 and U251), normal
brain tissue and tumor resection specimens (Figure 1A). NNAT
expression was found to be absent in the medulloblastoma cell line
DAOY, as well as the two glioma derived cell lines. NNAT was
found to have low expression in normal brain, but was abundant
within pituitary adenoma, a known positive control [8]. We
further confirmed our western blot findings with immunohisto-
chemistry and immunofluorescent staining (Figure 1B). Consistent
with western blot data, normal brain tissue exhibited a small
population of cells that express NNAT. These cells commonly
exhibited glial morphology. Contrarily, NNAT expression in
GBM samples yielded populations of cells that stained richly for
NNAT.
NNAT is overexpressed without mutation in a subset of
primary GBMs with EGFR expansion
After validating the NNAT antibody, we sought to assess the
prevalence of NNAT expression within resected GBM samples.
We initially evaluated 13 GBMs and identified NNAT expression
through western blot analysis (Figure 2A). We found 2 out of 13
GBM samples showed NNAT expression above the levels within
normal tissue. We next performed western blot analysis on a series
of gliomas with different WHO pathologic grades (Figure 2B).
NNAT was found to be absent in WHO Grade II (5 out of 5) and
Grade III (5 out of 5) gliomas, but was expressed higher than
normal baseline levels in 2 out of 5 cases of WHO Grade IV
gliomas (GBM). A total of 23 GBMs were assayed for the presence
of NNAT, and 4 of them were found to have increased NNAT
expression compared to normal brain tissue. Clinical patient data
verified that these tumors had presented as de novo lesions with a
pathologic diagnosis of WHO Grade IV at their onset.
The absence of NNAT expression within lower grade astrocy-
tomas (Grade II and III) prompted us to question whether its
expression is limited to primary de novo GBMs. Subsequently, we
assessed for over expression of EGFR, a finding strongly associated
with primary GBMS, among NNAT positive tumors and found all
of them to be strongly positive for EGFR over expression
(Figure 2C). We then questioned whether the aberrant expression
of NNAT might be due to a genetic mutation within the NNAT
genome and sequenced the coding regions of the NNAT gene in
all 23 GBM samples. None of the tumors were found to harbor
any exonal mutations.
High NNAT expression is associated with poor survival in
GBM patients
A summary of patient characteristics in the survival analysis is
detailed in Table 1. Among the 59 patients studied, 23 harbored a
tumor with high NNAT expression. Median survival time for
patients with high NNAT expression was 11.1 months, in contrast
to 18.9 months in patients with low NNAT expression. This
difference is statistically significant in univariate analysis (P,0.001,
Figure 2D). Results of the multivariate analysis using the Cox
proportional hazards model is detailed in Table 2, and revealed
that high NNAT is an independent prognostic factor indicating
shorter overall survival (P = 0.006). In addition to NNAT
expression, older age and low Karnofsky score were additional
factors associated with poor prognosis, whereas the extent of
resection was not found to be a significant prognostic factor in this
patient population.
NNAT expression drives cellular proliferation
The high expression of NNAT limited to a subset of primary
GBMs indicates its potential functional impact in tumor growth
and cell proliferation. Prior studies have found NNAT to be a
potent stimulator of cellular proliferation in medulloblastoma cells
[5]. To determine if NNAT plays an analogous role within
gliomas, we established U87 malignant glioma cell lines with stable
NNAT expression. The constructs of the two spliced forms of
NNAT, NNATa-EGFP and/or NNATb-DsRed were delivered
into U87 malignant glioma cells and selected through two rounds
of fluorescent assisted cell sorting (Figure 3A). Confocal micros-
copy revealed that NNATa (green) was expressed homogeneously
in the cytoplasm of U87 cells, whereas NNATb (red) located as
punctuated aggregation around the nucleus (Figure 3B). When co-
expressed in the same cell, NNATa and NNATb were found to be
co-localized as punctuated structures in the cytoplasm, indicating
potential heterodimer interactions.
The impact of NNAT on tumor cell growth was first assessed
through the MTT proliferation assay (Figure 3C), in which
NNATa and NNATb increased cell proliferation by 13.8% and
5.8%, respectively (P,0.05 vs. control), with coexpression of both
isoforms enhancing proliferation by 29.2% (P,0.01 vs. control
and single isoforms). Further analysis through EdU-derived high
content cell cycle screening revealed dramatic changes in the
population of S-phase cells across the cells lines (Figure 3D). The
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percentage of S-phase cells in the control U87 MG line was
29.8%, while in the NNATa and NNATb transfected lines, the
percentage rose to 79.9% and 54.7%, and in the co-expression line
it increased to 60.1%.
Discussion
Using our high throughput proteomic technique, CIEF-nRPLC-
MS, we identified a number of novel differentially expressed
membrane proteins in GBM TSCs versus their differentiated
counterparts. NNAT was identified and selected for further
investigation due to its previously described role in embryologic
CNS development as well as its association with more aggressive
phenotypes of medulloblastoma [5,9]. When surveyed across 23
different GBM tumors, NNAT showed elevated baseline expression
in 4 of them (17%). More interestingly, NNAT expression was not
found in any of the lower WHO grade II and III astrocytomas
(Fig. 2). In a larger cohort, we found that high NNAT expression is
associated with poor survival in GBM patients. This might be due to
the biological function of NNAT itself, promoting cell proliferation
and tumor growth, or simply reflecting a higher abundance of
NNAT expressing GBM TSCs in these more aggressive tumors.
Figure 1. Validation of NNAT Antibody. We selected a commercial polyclonal antibody (abcam, ab30332) targeting the C-terminus of both
NNAT isoforms for use in our study. To verify its specificity, we probed several tumor cell lines, normal brain, and pituitary adenoma samples as a
positive control through western blot (A) and combined immunohistochemistry and immunofluoresence (B). The antibody was specific in identifying
a band corresponding to the molecular weight of NNAT within positive control samples. Normal brain tissue exhibited endogenous NNAT expression
in a subset of astrocytes. A small proportion of GBMs strongly stained for NNAT with cytoplasmic and membrane localization.
doi:10.1371/journal.pone.0037811.g001
Figure 2. NNAT is Expressed in a Subset of Primary GBMs. (A)
We initially surveyed 13 GBM samples for NNAT expression and found
higher than baseline levels in 2 of the samples. (B) NNAT expression was
not found in 10 WHO Grade II and III tumors, but was positive in an
additional 5 GBM samples. A total of 23 GBM samples were assayed that
overexpression of NNAT was found in 4 (17%) of the samples. (C) All
tumors that expressed NNAT also had concurrent upregulation of the
EGFR receptor, a feature that is associated with primary GBMs that arise
de novo.
doi:10.1371/journal.pone.0037811.g002
Table 1. Patient demographics.
NNAT high NNAT low r
Total Patients 23 36
Male/Female 16/7 12/13 0.22
Median Age 63.4 56.1 0.06
Median KPS 90 90 0.66
GTR (%) 31.0 34.8 0.96
doi:10.1371/journal.pone.0037811.t001
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This latter finding may correlate with a recent distinction made
between primary and secondary GBMs based on the sequential
genetic aberrations that occur in tumors presenting in two separate
patient populations [10,11]. Primary GBMs present in older
patients with a mean age greater than 50 years old and are
characterized by overexpression of a mutated form of epidermal
growth factor receptor (EGFR), deletions in the phosphatase and
tensin homolog (PTEN) gene in chromosome 10, and p16 deletion
[12–14]. Secondary GBMs occur in younger patients and present as
a recurrence of an earlier lower WHO grade tumor that has
undergone malignant progression. These tumors typically show
overexpression of the platelet derived growth factor receptor
(PDGFR), mutations within p16, and aberrations within the p53
gene [12,15]. Within secondary GBMs, the accumulation of these
mutations is seen early in the malignant progression of the tumor,
with p53 mutations as well as PDGFR over-expression seen in
.60% ofWHOgrade II and III astrocytomas [11]. The presence of
NNAT expression in none of the lower grade tumors, suggests that it
may play a distinct role in the pathobiology of primary GBMs,
specifically within the recently characterized EGFR genetic subtype,
and excluded from the NF1 and PGFRA/IDH1 subtypes [16].
Current knowledge regarding the functional role of NNAT is
still limited. Structurally, NNAT belongs to the proteolipid family
of proteins and is thought to be membrane associated due to
having an N-terminus that is heavily enriched with hydrophobic
amino acids. Multiple studies examining other cell types have
found NNAT localization to be robust not only on the cell
membrane, but also in the cytoplasm as well [17–19]. The
significance of this compartmentalization is unknown, but such a
distribution may reflect vesicular trafficking of NNAT or its active
interplay with other signal transduction intermediaries. In
humans, NNAT is alternatively spliced with an a and b isoform
that differ by a 81-bp transmembrane sequence in the middle of
the coding region present within the a isoform. Human NNAT
mRNA is most abundantly expressed in the human fetal brain at
18–24 weeks of development, and undergoes down-regulation
during adulthood except in the anterior pituitary gland [8]. In
mice, NNAT expression also occurs early in fetal development,
with NNATa expression preceding and ending sooner than the
appearance of NNATb [9]. Spatially within the fetal mouse brain,
NNAT expression is first seen specifically within rhombomeres 3
and 5, the origins of the hindbrain, prior to becoming generalized
throughout the CNS [6]. The spatial and temporal pattern of
NNAT expression suggests that it participates in segment identity
of the developing mammalian brain, as well as maintenance of
developing as well as post-mitotic neuroepithelial cells.
Previous studies in medulloblastoma show that expression of both
NNAT isoforms is associated with increased proliferation and
anchorage independent growth, but that the presence of NNATa is
the primary determinate of cytologic response [5,20]. Our results
parallel this finding within U87 glioma cells, showing that
expression of both NNATa and NNATb is associated with
increased U87 proliferation by MTT assays as well as an increased
proportion of cells active in S-phase (Fig. 3 C, D). We also found the
proliferative effects of NNATa to be greater than NNATb, but co-
expression of both isoforms produced a greater than additive effect
seen in the MTT proliferation assay that could not be explained by
cell-cycle dependence (Fig. 3C). One possible explanation is that the
expression of both isoforms not only increases cellular proliferation,
but also enhances cellular viability in regards to anchorage-
dependent growth and other culture stresses. Furthermore, this
additive effect suggests that the two NNAT isoforms may interact,
which is further supported by our finding that the cellular
distribution of NNATa becomes more cytoplasmic when coex-
pressed with NNATb and that the two strongly colocalize (Fig. 3B).
The signal transduction pathway that mediates these proliferative
responses is currently unknown. However, other members of the
proteolipid family of proteins function as modulatory subunits of ion
channels with C-termini that can serve as adaptor sites for other
regulatory and signaling proteins [7,21].
The evidence we have accumulated suggests that NNAT is
present within normal human brain tissue limited to a specific
population of astrocytes (Fig. 1), is overexpressed in a subset of
primary GBM (Fig. 2), and strongly corresponds with elevated in
vitro proliferation (Fig. 3 C, D). It is tempting to hypothesize that
those astrocytes may be the very antecedent cells that undergo
malignant transformation and or dedifferentiation to form GBM
TSCs. However, we were not able to identify any mutations in the
NNAT coding region from our 23 GBM tumor samples that could
act as a trigger for this aberrant expression. Other possibilities that
cannot be excluded at this time are intronic regulatory unit
mutations, increased upstream signaling, or loss of epigenetic
regulation. Given the limited subset of GBMs that NNAT is
expressed within, it is unlikely to be a primary driver of GBM
pathogenesis, but rather may be secondarily induced through a
bystander effect due to derailment of other molecular signaling
pathways. However, given what little is known about NNAT,
especially with regard to primary CNS malignancies, it is a
promising target for further study that is likely to shed light on
novel signaling pathways involved in GBM pathobiology as well as
potential therapeutic targets for intervention.
Materials and Methods
Clinical materials
All tissue samples and clinical information were obtained as part
of an institutional review board-approved repository program at
the Surgical Neurology Branch at the National Institute of
Neurological Disorders and Stroke at the National Institutes of
Health, the Brain Tumor Institute at the Cleveland Clinic
Foundation and the Department of Neurosurgery at the Univer-
sity of Regensburg Medical Center. For this study, the authors
obtained IRB approval at their respective institutions to use both
fresh frozen glioma tissue specimens as well as normal human
brain tissue. Tumor samples were evaluated by the respective
pathology department of their originating institution to ensure
proper WHO tumor diagnosis, grading, as well as exclusion of
samples taken from tumor margins with large quantities of normal
brain tissue. Informed consent for usage of these samples was
waived by each respective IRB on the basis of adherence to the
‘Privacy Rule’, where all work utilized tissues from an existing
repository and that usage of research specimens posed no more
than a minimal risk to the privacy of the sample donors.
Table 2. Cox Proportional Hazards Data.
Hazard Ratio 95% CI r Standard Error
Low High
NNAT (+) 7.44 1.17 2.64 0.006 0.21
Age 6.32 1.00 1.04 0.012 0.11
KPS 3.87 6.5 10.0 0.049 1.58
Extent of resection 0.07 1.00 2.00 0.798 0.06
doi:10.1371/journal.pone.0037811.t002
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Patient population
For the survival studies, clinical data and tumor specimens from
a cohort of 59 consecutive patients (20 female, 39 male) treated at
the University of Regensburg Medical Center were investigated.
Mean age of the patients was 59.5 years (range, 33.6 to 82.5 years),
the median Karnofsy Performance Score was 90, (range, 50 to
100). All patients underwent initial craniotomy for tumor
resection. After resection, patients received combined adjuvant
treatment consisting of external beam radiation and chemotherapy
with temozolomide according to the Stupp regimen [22].
GBM TSC line and cell lines
Primary TSC cultures from freshly procured human GBM
tumors were obtained and expanded as previously described [3].
TSCs were grown in poly-d-lysin/laminin coated dishes with
DMEM/F12 medium (Invitrogen; Carlsbad, CA) supplemented
with N-2 (0.56; Invitrogen), B-27 without vitamin A (0.56;
Invitrogen), fibroblast growth factor (20 ng/ml; Invitrogen), and
epidermal growth factor (20 ng/ml; R&D Systems) that was
changed daily. Induction of TSC differentiation was carried out by
addition of ciliary neurotrophic factor (20 ng/ml; R&D Systems).
Figure 3. Expression of NNAT is Associated with Increased Cellular Proliferation. GFP-tagged NNATa and RFP-tagged NNATb were
transfected alone or in conjunction into U87 glioma cells. The cells were grown in antibiotic selection media utilizing G418 and underwent FACS (A)
repeatedly over the course of 5 weeks to select a stably transfected population with at least 2 log-fold increase in fluorescent protein expression
compared to controll. (B) The cellular distribution of NNATa was predominantly membrane bound, with some cytoplasmic localization as well. NNATb
was more strongly localized in the cytoplasm, and when coexpressed, the two isoforms were found to strongly co-localize with NNATa expression
moving more into the cytoplasm. (C) Utilizing a colorimetric MTT proliferation assay, expression of either form of NNAT dramatically increased the
proliferation profile of the U87 cells versus control. Coexpression of both isoforms caused an increase in proliferation that was greater than
expression of either isoform alone. (D) Using a fluorescent activated cell sorting based proliferation demonstrated high percentage of S-phase cells in
the NNATa (79.9%) and NNATb (54.7%) cell lines versus control (29.8%). Coexpression of both NNAT isoforms also yielded a higher population of S-
phase cells (60.1%).
doi:10.1371/journal.pone.0037811.g003
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Human medulloblastoma cell line DAOY, glioma cell lines U87
MG and U251 were maintained in Dulbecco’s Modified Eagle
Media (DMEM, Invitrogen) containing 10% FBS, 100 U/mL
penicillin and 100 mg/mL streptomycin.
CIEF-nRPLC-MS proteomic profiling
Samples of TSCs prior to and after treatment with CNTF were
harvested for proteomic profiling by Calibrant Biosystems
(Gaithersburg, MD), as previously described [23]. Briefly, collected
cells were digested by trypsin, and fractionated into 12 fractions by
CIEF. The fractions were then sequentially analyzed through
nRPLC and fed into a quadrupole time-of-flight micro mass
spectrometer (Waters, Milford, MA). Peptide and protein identi-
fications were then made using MASCOT 2.0 (Matrix Science,
London, UK) utilizing a reversed proteome database search
approach. The incidence of unique tryptic peptides were then used
to assess relative quantities of their corresponding protein and a
comparison of proteomic profiles between native and differenti-
ated TSCs was made.
Western blot and antibodies
Microdissected tissue and cell pellets were collected and lysed in
T-PER lysis buffer (Thermo), sonicated, and centrifuged. The
quantity of protein was determined using a colorimetric Bio-Rad
Protein Assay Kit (Bio-Rad). Proteins were separated on NuPAGE
4 to 12% Gradient Bis-Tris gels (Invitrogen) and transferred to
PVDF membranes. Membranes were blocked in 5% skim milk in
TBS with 0.05% Tween-20 and probed with primary antibody.
Visualization was carried out through a species specific horserad-
ish peroxidase conjugated secondary antibody system paired with
the Pierce SuperSignal West Pico enhanced chemilumescent
substrate (Thermo; Rockford, IL).
Antibodies used in this study: EGFR (4267S, Cell Signaling
Technology), GFAP (3670S, Cell Signaling Technology), Nestin
(ab22035, Abcam), NNAT (ab27266, Abcam), b-Actin (sc-47778,
Santa Cruz), Sox2 (3579S, Cell Signaling Technologies).
Immunostaining
Cells or tissue slices were fixed in Histochoice H108 (Mandel;
Guelph, Ontario, Canada) and incubated in 0.3% Triton X-100/
TBS before being blocked with 5% BSA/TBS and subsequently
labeled with anti-NNAT (1:100, Abcam) antibodies overnight. For
immunofluorescence studies, visualization utilized a species
specific Alexa Fluor conjugated secondary antibody (Sigma)
followed by nuclear counterstaining with Hoechst 33342 (Invitro-
gen) before examination using a Zeiss LSM510 confocal micro-
scope. Immunohistochemistry studies utilized a species specific
horseradish peroxidase conjugated secondary antibody paired with
the VECTASTAIN ABC System (Vector Laboratories, Burlin-
game, CA) for colorimetric detection. The specimens were then
examined using a Leica DM LB light microscope. Grading of
immunohistochemical staining was performed by three observers
who were blinded to the clinical outcome of the patients. The
rating of the immunohistochemical staining was performed by
using a four-grade, semiquantitative scale (1, no cells positive; 2, 1
to 10% positive; 3, 10 to 30% positive; 4, more than 30% positive).
High NNAT expression was defined by an average rating higher
than grade 3 for each patient.
NNAT Sequencing
DNA extraction from human GBM tumors was performed
using the Qiagen DNeasy Blood and Tissue Kit (Qiagen, Valencia
CA). Genomic DNA was utilized as a template for polymerase
chain reaction targeting the 3 coding regions of NNAT. The
primers are as follow: Exon 1 ( Forward – 59TTTCTCGAC-
CACCCACCTAC; Reverse – 59CGGCAATCGGAATAGCAC),
Exon 2( Forward – 59TGCCAAAGGAATCGCATATT; Reverse
– 59GCTGATTGGACCCACAACTT), Exon 3( Forward –
59GTGGGTGCTCTCCACTAAGG, Reverse – 59AGGAG-
CACCTGATGATACGG). Sequencing was subsequently per-
formed at the NINDS DNA Sequencing Facility and results were
aligned and analyzed using the ClustalW2 program available
online.
Stable Transfection of U87 MG Cells
The full-length human cDNA of the NNATa and NNATb
isoforms were inserted into pCMV6 mammalian expression
vectors. To distinguish the two transcriptional variants, NNATa
was fused with an EGFP tag, whereas NNATb was fused with a
DsRed tag. Twenty-four mg of NNATa-EGFP or NNATb-DsRed
vector was delivered into 1.06107 U87 MG cells with lipofecta-
mine 2000 reagent (Invitrogen). Media was replaced on the fifth
day with selection media containing 400 mg/mL G418 and the
lines were maintained in selection media for 2 weeks. Stable clones
were isolated through three rounds of fluorescence-activated cell
sorting (FACS) as previously described [24]. Cells with .95%
purity were maintained in DMEM containing 10% FBS, 100 U/
mL penicillin and 100 mg/mL streptomycin for subsequent
analysis.
Proliferation and Cell Cycle analysis
To visualize cell cycle changes, stable transfected U87 MG cells
were labeled with 20 mM EdU (Invitrogen) for 4 hours. Cells were
then labeled using Click-iT EdU HCS assay kit with either Alexa
Fluor 488 or pacific blue labeling. DNA was counterstained with
DRAQ5 (5 mM, Cell Signaling Technology). Cells were analyzed
using an Image Stream X flow cytometry system (Amnis). IDEAS
software was used to acquire and quantify fluorescent signal
intensities and to graph the data as bivariate dot density plots for
cell cycle determination.
Statistics
Comparative significance testing of continuous variables was
performed using the students t-test with a significance threshold
defined at P,0.05. For the clinical analysis, survival time was
measured from the date of resection until death of the patients.
Survival rate was calculated by the Kaplan–Meier method and
comparisons of survival between the different groups were
estimated by generalized Wilcoxon test for univariate analysis.
For multivariate analysis, Cox’s proportional hazards model
(forward stepwise procedure) was used. In addition to NNAT
expression, age, Karnofsky score, and the extent of resection were
analyzed as potential prognostic factors(SPSS Version 17.0, SPSS
Inc., Chicago IL).
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